📰 Product Testing News
Page 44 - Product Testing News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Product Testing. Real-time updates on events, politics, business and more.
February 11, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation. FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol February 11, 2021 GMT TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ -- Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is characterized by extremely high low-density lipoprotein cholesterol (LD...
February 11, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation. Advanced Chemotherapy Technologies, Inc. Announces $2.5M Series A Investment by Spectrum Financial February 11, 2021 GMT Advanced Chemotherapy Technologies ACT-IOP-003 iontophoresis chemotherapy delivery system (Photo: Business Wire) RALEIGH, N.C.--(BUSINESS WIRE)--Feb 10, 2021-- Advanced Chemotherapy Technologies, Inc., a clinical-stage drug delivery company, announced today that it has closed a Serie...
February 11, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation. Global Pyrazinamide Market to Surpass US$ 163.1 Mn by 2027, Says Coherent Market Insights (CMI) February 10, 2021 GMT According to Coherent Market Insights, the Global Pyrazinamide Market is estimated to be valued at US$ 143.9 Mn in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027). Key Trends and Analysis of the Global Pyrazinamide Market: ADVERTISEMENT Tuberculos...
February 11, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal ... Myovant Sciences, Inc.February 11, 2021 GMT ORGOVYX™ (relugolix) approved by the U.S. Food and Drug Administration (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021 Announc...
February 11, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation. AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience February 11, 2021 GMT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2021-- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-concept study (CHARMS) evaluating the company’s lead product candidate, Viralym-M (ALVR105...
February 11, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation.
February 11, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation.
February 10, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
February 10, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients ... AIM ImmunoTech Inc.February 10, 2021 GMT OCALA, Fla., Feb. 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Dutch Health and Youth Care Inspectorate (IGJ) has approved treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Prog...
February 10, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.